BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26839934)

  • 1. Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):69-71, 45-8. PubMed ID: 26839934
    [No Abstract]   [Full Text] [Related]  

  • 2. vilanterol + fluticasone (RELVAR Ellipta). Asthma and COPD: yet another beta-2 agonist and corticosteroid combination.
    Prescrire Int; 2016 Apr; 25(170):94. PubMed ID: 27186620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG; Prosser TR
    Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
    Solidoro P; Patrucco F; Bagnasco D
    Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
    McKeage K
    Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relvar Ellipta for asthma.
    Drug Ther Bull; 2014 Aug; 52(8):93-6. PubMed ID: 25125553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Caramori G; Ruggeri P; Casolari P; Chung KF; Girbino G; Adcock IM
    Expert Rev Respir Med; 2017 Dec; 11(12):955-967. PubMed ID: 28956463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trelegy Ellipta--a three-drug inhaler for COPD.
    Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluticasone-vilanterol combination approved for COPD.
    Traynor K
    Am J Health Syst Pharm; 2013 Jun; 70(12):1008. PubMed ID: 23719869
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Capuano A; Cazzola M
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vilanterol fluticasone and mortality in comorbid COPD GOLD B.
    Brusselle G
    Lancet; 2016 Apr; 387(10030):1791-2. PubMed ID: 27203487
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
    Wolthers OD
    Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ; Neffen H
    Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD).
    Lal C; Strange C
    Expert Opin Pharmacother; 2019 Jun; 20(9):1075-1085. PubMed ID: 30983423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lung study promising a breath of fresh air in research world.
    Limb M
    BMJ; 2015 Nov; 351():h6343. PubMed ID: 26613902
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Umeclidinium/vilanterol fixed-dose combination for COPD.
    Gras J
    Drugs Today (Barc); 2014 Mar; 50(3):231-8. PubMed ID: 24696868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.